Summary Using a bacterial fusion protein, a deleted colorectal carcinoma (DCC)-specific monoclonal antibody (MAb) 127-22 was established. Although MAb 127-22 reacted with almost all normal tissues, it did not react or only weakly reacted with many cancer cell lines, including colonic cancer lines, in flow cytometry. In Western immunoblots, the MAb reacted with a single 1 90-kDa molecule in a myeloma line Ara-10 extract. This component was scarcely detected in colonic cancer cell lines. Immunoblots of samples from 25 pairs of colonic cancers and adjacent normal tissues and from five adenoma tissues revealed that all normal colonic and adenoma tissues significantly expressed the DCC protein, whereas colonic cancer tissues showed poor expression. These results indicate not only deletion of and lowered mRNA expression of the DCC gene, but also marked reduction of DCC protein occurred in colonic cancer tissues. In addition, colonic cancer patients with liver metastasis expressed significantly lower levels of DCC than those without, suggesting the prognostic value of DCC expression.
The development of human cancer has been proposed to be a multistep process (Nowell, 1986) . Vogelstein et al (1988) showed that colonic tumorigenesis provides the systematic course to the multistep hypothesis at the molecular level. Several genes have been identified that alter during tumour progression. Frequent and consistent loss of heterozygosity (LOH) of specific chromosomes in human cancers has been associated with the presence of tumoursuppressor genes (Friend et al, 1986; Baker et al, 1989) . In particular, the long arm of chromosome 18 has been shown to be lost in about 75% of colonic cancers (Vogelstein et al, 1988) .
The tumour-suppressor gene DCC (deleted in colorectal carcinoma), located on the long arm of chromosome 18, encodes a cellsurface protein containing homology with N-CAM (Fearon et al, 1990 ). There have been many reports on the loss of heterozygosity at the DCC gene locus in human colon cancers (Kem et al, 1989 ; Kikuchi-Yanoshita et al, 1992; Itoh et al, 1993; Turley et al, 1995; Thiagalingam et al, 1996) , suggesting that DCC might be a tumour-suppressor gene. Some reports also claim marked reduction of the gene expression in colon cancers based on the results of reverse transcription polymerase chain reaction (RT-PCR). However, only a few studies have been performed on the alteration of DCC protein in colon cancer cells compared with that in normal cells (Hedrick et al, 1992 (Hedrick et al, , 1994 Shibata et al, 1996) .
In the present study, we generated a DCC-specific mouse monoclonal antibody (MAb) and analysed the expression levels of DCC proteins in various normal tissues, cancer cell lines and benign and malignant colonic tumours. Here, we demonstrate dramatic decreases of DCC protein as well as its mRNA in colon cancer tissues. Furthermore, we also investigated the clinical significance of the reduction of DCC expression in the diagnosis and treatment of colorectal cancer patients.
MATERIALS AND METHODS RT-PCR
Total RNA was extracted from ARA 10 (myeloma) using guanidinium thiocyanate (Chomczynski and Sacchi, 1987) . Singlestrand cDNA prepared from 3 gg of total RNA using Moloney murine leukaemia virus reverse transcriptase (GIBCO-BRL, Bethesda, MD, USA) with an oligo(dT)14 primer was used as the template for the polymerase chain reaction (PCR). The primers for PCR to amplify the DCC gene-coding region were as follows: the 5' primer DCC-AX encompassed positions 208-224 of the published human DCC sequence (Fearon et al, 1990) , 5'-GGGGATCCC-CAGTGATCAAG TGGAA-3' (contained a BamHI site); the 3' primer DCC-BX encompassed positions 416-432, 5'-GGGAATT CTGAAAGGAACCTCAGTG-3' (contained an EcoRl site) (Fearon et al, 1990) . These primers and an oligo(dT)14 primer were constructed using a 380B DNA synthesizer (Applied Biosystems, Tokyo, Japan Preparation and affinity purification of bacterial extracts This is performed principally as described by Smith and Johnson (1988) . In brief, overnight bacterial cultures were diluted 1:10 (to 400 ml) in fresh medium and incubated for 2 h. Yamashiro et al (1993) .
Flow cytometry
Flow cytometry was performed as described previously (Yamashiro et al, 1993) . Briefly, the cells were incubated with appropriately diluted MAb for 45 min on ice. After two washes with phosphate-buffered saline (PBS), the cells were incubated with 100 g1 of 100-fold-diluted fluorescein isothiocyanate (FITC)-conjugated anti-mouse IgG (Cappel, West Chester, PA, USA) for 30 min on ice. After two washes, the cells were examined using a FACScan (Becton-Dickinson, Mountain View, CA, USA).
Western blot
Cells were lysed in 0.01 M Tris buffer, pH 7.3, containing 0.15 M sodium chloride, 0.01 M magnesium chloride, 0.5% NP-40, 1 mm phenylmethylsulphonyl fluoride (PMSF) (Sigma, St Louis, MO, USA) and 20 U ml-' of aprotinin (Bayer, Leverkusen, Germany). Usually, 100 jig of protein determined using the Bradford method (Bradford, 1976) was resolved by SDS-PAGE according to Laemmli (1970) and transferred to a PVDF membrane (Immobilon, 0.22-,um pore size) (Nihon Millipore Kogyo KK, Tokyo, Japan) for 4.5 h at 70 V in blotting buffer consisting of 0.025 M Tris, 0.192 M glycine and 20% methanol. The protein blots were incubated in PBS with 5% non-fat dry milk (Yukijirushi, Sapporo, Japan) and 0.02% sodium azide at 4°C overnight. The membranes were incubated with MAb DCC 127-22 at room temperature for 1 h and washed with T-PBS (PBS containing 0.05% Tween-20) three times. Proteins were immunodetected using the Vectastain ABC kit (Vector Laboratories, Burlingame, CA, USA) according to the manufacturer's instructions. The proteins were visualized using a Konica immunostaining HRP kit (Konica, Tokyo, Japan). The intensity of the bands was measured by a densitometer (Yamashiro et al, 1995) , and the ratio of the DCC bands in cancer tissues to those of the adjacent normal mucosa was calculated. Data were presented as the mean ± standard deviation. Statistical analysis was performed by the chi-square test. Differences were taken as being significant when the P-value was less than 0.05. (Bradford, 1976 Immunohistochemistry of normal human tissues and colonic cancers using MAb 127-22
The expression of DCC in normal human tissues was analysed using immunohistostaining. All tissues expressed some levels of DCC, although there were some differences in the intensities of the staining. Colonic cancer tissue and corresponding normal tissue were then examined using immunohistochemistry. For normal tissue, the staining was intense, mainly on the apical aspect of the cells, while colonic cancer tissue was not stained ( Figure  4A ). Figure 4B shows a high magnification of the border between colon cancer tissue and normal tissue and demonstrates a distinct staining pattern.
British Journal of Cancer (1998) Decreased expression of protein in colonic cancer The expression of DCC protein in colonic cancers, adjacent normal mucosae and adenomas was analysed by immunoblotting using Representative examples are shown in Figure   5 . Prominent 190-kDa bands of DCC were observed in the extracts from normal colonic mucosae and adenomas, whereas bands were undetectable in the extracts from corresponding colonic cancers. In all samples examined, DCC protein was more prominently expressed in the adjacent normal colonic mucosae and adenoma tissues than in the colonic cancer tissues. Figure 6 is Liver metastasis and DCC expression Among 25 colon cancer tissues, 15 samples with no liver metastasis showed significantly higher levels of DCC than ten samples with liver metastasis as shown in Figure 7 . These results indicate the possible use of DCC as a prognostic factor in colon cancer patients.
DISCUSSION
Since DCC was discovered by Vogelstein et al in 1990 (Fearon et al, 1990 , there have been many reports describing the high frequency of LOH at the DCC locus in the colon cancer tissues lacopetta et al, 1994; lino et al, 1994) , and in many other cancers (Hohne et al, 1992; Miyake et al, 1994; Murty et al, 1994; Kashiwaba et al, 1995; Cho et al, 1996) . DCC has been evaluated as a tumour-suppressor gene candidate on chromosome 18 in colorectal cancers (Thiagalingam et al, 1996) . RT-PCR approaches have also been used to show lower expression of the DCC gene in colon cancer tissues compared with adjacent normal colonic mucosae (Kikuchi-Yanoshita et al, 1992; Itoh et al, 1993; lino et al, 1994) . However, only a few reports on the DCC protein levels in colon cancer and normal colonic tissues in individual patients have been published. Protein analysis has been reported in normal tissues (Turley et al, 1995) , for leukaemia and MDS (Inokuchi et al, 1996) and for brain tumours (Ekstrand et al, 1995) .
In the present study, we have established a DCC-specific MAb by using a GST-DCC fusion protein for immunization. This MAb proved to be very useful in Western immunoblot, flow cytometry and immunohistostaining. As expected, DCC protein was scarcely detectable in human cancer cell lines, except for some haematopoietic lines. Colon cancer tissues from patients were also negative or they expressed at a very low level. On the other hand, normal colonic tissues -and adenoma tissues showed almost equivalent intensities of DCC bands in immunoblots. These results are very similar to the immunohistochemical studies reported recently by Shibata et al (1996) . The fact that five adenomas showed equivalent expression levels to normal tissues suggested that the reduction observed in carcinomas is a relatively late phenotypic event.
These results indicate that DCC may play an important role as a tumour-suppressor gene, and down-regulation or defect of the gene may trigger progression of colon cancers from adenomas.
The immunoblot results of DCC showed fairly broad variations in the cancer/normal expression ratio between samples as shown in Figures 6 and 7 . This may be partly due to varying levels of contamination of non-tumour tissue present in each case. The data for cancer cell lines in which DCC bands could be scarcely seen also suggest this possibility.
Furthermore, it has been demonstrated that the inactivation of the DCC gene or reduction of DCC gene expression closely correlates with cancer metastasis. Recent studies have indicated the importance of DCC alterations in liver metastasis (Itoh et al, 1993; Ookawa et al, 1993; lino et al, 1994; Kato et al, 1996) or nodal metastasis (Kataoka et al, 1995) of colorectal cancers. Our quantitative data of DCC protein also indicate a reverse correlation between DCC levels and frequency of liver metastasis in colon cancers, suggesting its value as a prognostic marker. As the observation time after operation was not long enough, the prognosis of each patient has not been examined. However, the results shown in Figure 7 may be useful in identifying primary tumours likely to have liver metastases. The study of a larger number of tumours is also needed.
As for the biological function of DCC, no definite roles of the molecule have been elucidated so far. As DCC has high homology with N-CAM, one of the adhesion molecules abundantly expressed in nervous tissues, it might play an important role in cell-cell or cell-extracellular matrix interaction during development or differentiation . Some reports strongly indicate that DCC is important for cell differentiation (Hedrick et al, 1994) , particularly in the differentiation of neuronal cells (Laelor and Narayanan, 1992) . Recently, Goyette has shown that chromosome 18 restores TGF-3 responsiveness and reduces tumorigenicity in the human colonic carcinoma cell line SW480. It may be important to determine whether the DCC gene is sufficient to restore responsiveness to TGF-1 and suppress tumorigenicity. In fact, transformed epithelial cells have been reversed from the malignant phenotype by the introduction of the DCC gene (Klingelhutz et al, 1995) . Further understanding of the biological functions of DCC will provide more effective methods of its application for diagnostic and therapeutic purposes.
